Announcing Veeva AI

Rhea-AI Summary

Veeva Systems has announced Veeva AI, a major initiative adding artificial intelligence capabilities to their Vault Platform and applications. The AI enhancement aims to boost productivity across clinical, regulatory, safety, quality, medical, and commercial sectors through AI Agents and AI Shortcuts.

The platform will feature application-specific AI Agents that understand context, include safeguards, and securely access Veeva data. Users can customize these agents and create new ones for specific needs. AI Shortcuts allow users to set up personal automations for common tasks.

Key features include:

• LLM-agnostic design supporting major language models
• Flexible deployment with Veeva-supplied or customer-specific LLMs
• Secure data handling for each customer
• Simple subscription fee structure

The first release is scheduled for December 2025, with licensing at the Vault level.

Positive

• Major AI integration across all Veeva applications from clinical to commercial, potentially increasing operational efficiency
• Platform agnostic approach supporting multiple LLMs, offering flexibility to customers
• Revenue potential through new subscription-based licensing model at Vault level
• AI integration designed for quick deployment with existing applications, reducing implementation costs
• Customizable AI Agents allowing company-specific use cases, increasing product value proposition

Negative

• Implementation timeline extends to December 2025, potentially lagging behind competitors
• Additional subscription fees required for AI features may impact customer adoption
• Dependency on third-party LLMs could pose integration and performance risks

Insights

Technology Analyst

Veeva's AI initiative strengthens its life sciences software platform with industry-specific automation, creating new revenue opportunities while maintaining security and compliance.

Veeva Systems (NYSE: VEEV) has announced a major strategic initiative called "Veeva AI" that will integrate artificial intelligence capabilities across their entire application suite. This represents a significant product enhancement that could strengthen Veeva's competitive positioning in the life sciences software market.

The technology features two key components: AI Agents that understand application context with built-in safeguards, and AI Shortcuts enabling user-specific task automation. Veeva's approach is notably LLM-agnostic, supporting most major language models while maintaining customer data security—customers can use Veeva-supplied LLMs or configure their own.

From a technology perspective, this initiative demonstrates strategic foresight in several ways. First, by embedding AI directly into existing applications rather than creating standalone tools, Veeva leverages its established market position. Second, the LLM-agnostic approach reduces technology risk as the AI landscape evolves. Third, applying AI to industry-specific functions creates targeted value that generic AI platforms cannot easily match.

The December 2025 release timeline indicates this is a forward-looking initiative rather than an immediate product launch. The subscription model at the Vault level with what Veeva describes as a "simple and reasonable subscription fee" suggests a potentially new revenue stream that could drive growth while encouraging broad adoption across their customer base.

Life Sciences Software Specialist

Veeva's AI integration addresses crucial productivity challenges in regulated life sciences workflows, potentially accelerating treatments to market while maintaining compliance.

For life sciences companies, Veeva's AI initiative directly addresses a critical industry challenge: implementing advanced automation in heavily regulated environments. By integrating AI capabilities into applications that already meet stringent compliance requirements, Veeva offers a potentially lower-risk path to AI adoption for pharmaceutical and biotech organizations.

The emphasis on application-specific AI Agents with built-in safeguards acknowledges the unique compliance requirements these companies face. This approach could significantly reduce implementation barriers compared to general-purpose AI solutions that would require extensive validation for life sciences use.

Particularly valuable is how the initiative targets productivity improvements across the entire product lifecycle—from clinical trials through regulatory submissions to commercial operations. These areas involve complex documentation, workflows, and knowledge management that are ripe for AI-powered efficiency gains.

CEO Peter Gassner's statement that this initiative will "help make AI simple, secure, and compliant for life sciences companies of all sizes" speaks to Veeva's understanding of industry pain points. The ability for customers to configure and extend AI Agents for company-specific use cases provides flexibility essential in an industry with diverse regulatory requirements and workflows.

By focusing on helping companies "ultimately get treatments to patients faster," Veeva positions this initiative as supporting the core mission of life sciences companies, potentially strengthening their strategic partnership position beyond being merely a software vendor.

Major new initiative will add AI to Veeva applications and the Veeva Vault Platform to help automate critical industry-specific functions and improve productivity from clinical to commercial

PLEASANTON, Calif., April 29, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva AI, a major new initiative that adds AI to the Veeva Vault Platform and Veeva applications to help life sciences companies automate tasks and improve employee productivity using AI Agents and AI Shortcuts. Veeva AI provides a fast and efficient way to introduce application-specific AI Agents based on large language models (LLMs) into existing Veeva applications and enable end users with AI Shortcuts. Veeva AI will work in all Veeva applications across all major areas, including clinical, regulatory, safety, quality, medical, and commercial.

Veeva AI Agents can be deployed quickly with high impact because they understand the Veeva application context, have application-specific prompts and safeguards, and have direct, secure access to Veeva application data, documents, and workflows. Customers can configure and extend Veeva-delivered AI Agents and build custom AI Agents to address company-specific use cases. AI Agents can be used through a chatbot user interface or called via the AI API.

Veeva AI Shortcuts empower end users with the ability to easily set up personal AI-powered automations to accomplish frequent user-specific tasks such as helping with workflows, generating insights, or researching a topic.

"GenAI is a new computing paradigm that will significantly increase productivity for knowledge workers," said Veeva CEO Peter Gassner. "Core applications give you structured data, business rules and workflow. They execute with the speed, consistency, and scale we expect from computers. GenAI brings the more human-like ability to derive answers and insights from ambiguous situations that deal with language, context, and broad-based knowledge. Core applications and GenAI working seamlessly together will bring significant productivity gains."

Veeva AI is LLM agnostic and will support most major large language models. Customers may use a Veeva-supplied LLM or configure Veeva AI to use a customer-specific LLM. Regardless of deployment or which LLM is used by a customer, Veeva AI keeps customer data secure for each customer.

"Our customers depend on Veeva applications for some of their most critical industry-specific processes from clinical to commercial. They want to use AI to improve productivity and ultimately get treatments to patients faster," said CEO Peter Gassner. "Adding Veeva AI to our core applications will help make AI simple, secure, and compliant for life sciences companies of all sizes."

The first release of Veeva AI is planned for December 2025 and will be licensed at the Vault level with a simple and reasonable subscription fee to encourage industry adoption that is both broad and thoughtful.

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services, including certain of our new solutions and applications that are still under development or not generally available. These statements are based on our current expectations. Actual results, availability, and any future events relating to these products and services could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:

Maria Scurry
Veeva Systems
781-366-7617
maria.scurry@veeva.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/announcing-veeva-ai-302440862.html

SOURCE Veeva Systems

FAQ

When will Veeva Systems (VEEV) launch its new AI initiative?

Veeva Systems plans to release Veeva AI in December 2025. The initiative will be licensed at the Vault level with a subscription fee model designed to encourage broad industry adoption.

What are the key features of Veeva's (VEEV) new AI platform?

Veeva AI includes two main features: AI Agents that integrate with existing Veeva applications and handle industry-specific tasks, and AI Shortcuts that allow users to create personal automations for frequent tasks. The platform is LLM-agnostic and maintains data security.

How will Veeva AI impact VEEV's healthcare customers?

Veeva AI will help life sciences companies automate critical tasks and improve productivity across clinical, regulatory, safety, quality, medical, and commercial operations. Companies can use pre-built AI Agents or create custom ones for specific needs.

What makes Veeva's (VEEV) AI platform different from other healthcare AI solutions?

Veeva AI is unique because it understands application context, has industry-specific prompts and safeguards, and has direct secure access to Veeva application data. It can be integrated with most major large language models and maintains customer data security.

How will Veeva (VEEV) price its new AI platform?

Veeva AI will be offered with a 'simple and reasonable subscription fee' at the Vault level, designed to encourage broad industry adoption while maintaining thoughtful implementation.